Global Health Pulse: Key Updates on Ebola, Cancer Drugs, and Obesity Treatments

The latest health news includes rising Ebola deaths in Congo, notable cancer drug deals by Roche and Incyte, and promising trials for obesity treatments. The USDA reports new screwworm cases, while the FDA approves a pediatric hemophilia drug. These developments highlight challenges and innovations shaping global health responses.

The Democratic Republic of Congo reports over 100 confirmed Ebola deaths, with armed conflict hindering efforts in the hardest-hit regions. This underscores the challenges faced in managing the Bundibugyo strain of the virus, which went undetected for weeks.

In the pharmaceutical sector, Roche partners with Nurix Therapeutics in a $2.3 billion deal focusing on the blood cancer drug bexobrutideg, set to advance to phase III trials. Meanwhile, Incyte expands its blood disorder treatment portfolio by acquiring Vega Therapeutics for up to $2 billion.

The U.S. Department of Agriculture confirms additional screwworm cases in Texas, affecting livestock, while the FDA approves Pfizer's new drug for pediatric hemophilia patients. As global health measures adapt, the focus remains on managing outbreaks and advancing treatment innovations.